Biote Corp. shares rise 1.63% intraday after Krystal Biotech's FDA approval of VYJUVEK.

Biote Corp. rose 1.63% intraday, with Krystal Biotech, Inc. announcing FDA approval of updated VYJUVEK, a non-invasive, topical, redo sable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. This approval is a significant milestone for the company, as it provides a new treatment option for patients with DEB, a rare and debilitating genetic skin disorder.